Novel lipophilic acetohydroxamic acid derivatives based on conformationally constrained spiro carbocyclic 2,6-diketopiperazine scaffolds with potent trypanocidal activity. by Fytas, Christos et al.
Fytas, C; Zoidis, G; Tzoutzas, N; Taylor, MC; Fytas, G; Kelly, JM
(2011) Novel Lipophilic Acetohydroxamic Acid Derivatives Based on
Conformationally Constrained Spiro Carbocyclic 2,6-Diketopiperazine
Scaffolds with Potent Trypanocidal Activity. Journal of medicinal
chemistry, 54 (14). pp. 5250-5254. ISSN 0022-2623
Downloaded from: http://researchonline.lshtm.ac.uk/264/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
S1 
 
Supporting Information 
Novel Lipophilic Acetohydroxamic Acid Derivatives Based on 
Conformationally Constrained Spiro Carbocyclic 2,6-
Diketopiperazine Scaffolds with Potent Trypanocidal Activity  
Christos Fytas†, Grigoris Zoidis†, Nikolaos Tzoutzas†, Martin C. Taylor‡, George Fytas*,†, John M. 
Kelly‡ 
†Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, 
Panepistimioupoli-Zografou, GR-15771, Athens, Greece 
 ‡Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine 
Keppel Street, London WC1E 7HT, U.K. 
*To whom correspondence should be addressed. Phone: +30210 7274810. Fax: +30210 7274747. 
E-mail: gfytas@pharm.uoa.gr 
Contents 
S2 Experimental. Chemistry 
S11 Antitrypanosome action of compounds 43-45, 27-31, 41, 56, 59, 71, 6a, 6b, 37-39, and 64-
67 (Table 2). 
S12 Experimental. Biological Assays. 
S13 Elemental Analysis data of the tested compounds synthesized in this study (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
S2 
 
Experimental 
Chemistry 
General. Melting points were determined using a Büchi capillary apparatus and are 
uncorrected. The 1H and 13C NMR spectra were obtained on either a Bruker MSL 400 (400 MHz 
1H; 100 MHz 13C) or Bruker 600 (600 MHz 1H) spectrometer, using CDCl3 or DMSO-d6 as 
solvent. Chemical shifts are reported in δ (ppm) with the tetramethylsilane or solvent (DMSO-d6) 
as internal standard. Spliting paterns are designated as s, singlet; d, doublet; dd, doublet of 
doublets; t, triplet; td, triplet of doublets; q, quartet; m, multiplet; br, broad; v br, very broad; sym, 
symmetrical. Coupling constants (J) are expressed in units of hertz (Hz).  The spectra were 
recorded at 293 K (20 oC) unless otherwise specified. Carbon multiplicities were established by 
DEPT experiments. The 2D NMR experiments (HMQC and COSY) were performed for the 
elucidation of the structures of the newly synthesized compounds. Low resolution mass spectra 
(MS) were measured either in chemical ionization (CI) in positive mode using methane as CI 
reagent gas or in electron impact (EI) on a Thermo Electron Corporation DSQ mass spectrometer. 
High resolution mass spectra (HRMS) were performed on a hybrid LTQ-Orbitrap Discovery 
spectrometer under electrospray ionization (ESI) in positive mode. Optical rotations were 
measured on a Perkin Elmer 341 polarimeter at the sodium D line (589). Analytical thin-layer 
chromatography (TLC) was conducted on precoated Merck silica gel 60 F254 plates (layer thickness 
0.2 mm) with the spots visualized by iodine vapors and/or UV light. Column chromatography 
purification was carried out on silica gel 60 (70-230 mesh). Elemental analyses (C, H, N) were 
performed by the Service Central de Microanalyse at CNRS (France), and were within ±0.4% of 
the theoretical values except where noted (compounds 10b.HCl and 38.HCl). Elemental analysis 
results for the tested compounds correspond to ˃95% purity. The commercial reagents were 
purchased from Alfa Aesar, Sigma-Aldrich, and Merck, and were used without further purification 
except for the benzyl bromoacetate. This reagent was purified by fractional distillation in vacuo 
prior to use. Organic solvents used were in the highest purity, and when necessary, were dried by 
the standard methods. Solvent abbreviations: THF, tetrahydrofuran; DMF, dimethylformamide; 
Et2O, ethyl ether; MeOH, methanol; EtOH, ethanol; AcOEt, ethyl acetate; DMSO, 
dimethylsulfoxide. 
The 1H and 13C NMR spectra for all hydroxamate derivatives described in this report 
(compounds 7a-e, 8, 9a-d, 10a, 10b, 32-36, 42, 60-63, 72, 73, and 45) and hydrazide 44, are 
consistent with a Z/E conformational behavior of these molecules in solution. The detected 
double set of characteristic peaks in 1H and 13C NMR spectra confirm the occurrence of the two 
carbonyl conformers. The assignment of the Z or E conformers was based on literature data 
concerning Z/E conformational isomerism studies in simple hydroxamate and hydrazide 
structures,24 and 2D NMR experiments.  
 
(24) (a) Brown, D. A.; Glass, W. K.; Mageswaran, R.; Mohammed, S. A. 1H and 13C NMR 
studies of isomerism in hydroxamic acids. Magn. Reson. Chem. 1991, 29, 40-45, and references 
therein. (b) Bouchet, P.; Jacquier, R.; Pereillo, J. M.; Elguero, J. NMR study of configuration of 
hydrazides. Bull. Soc. Chim. Fr. 1972, 6, 2264-2271. 
 
N-Hydroxy-3,5-dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetamide (7a) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 32 gave the title compound 7a as a white crystalline solid (96%): mp 193-195 οC 
(dec) (EtOH -Εt2O);  1H NMR (400 MHz , DMSO-d6) δ 1.43 (d, 2H, J=12.0 Hz, 4΄e, 9΄e-H), 1.55-
1.68 (m, 4H,  6΄, 8΄e, 10΄e-H), 1.75 (s, 1H, 7΄-H), 1.79 (s, 1H, 5΄-H),  1.94 (s, 2H, 1΄, 3΄-H), 2.25 (t, 
4H, J=10.6 Hz, 4΄a, 8΄a, 9΄a, 10΄a-H), 3.13 (t, 1H, J=7.8, 8.4Hz, 1-H), 3.56 (d, 2H, J=8.4Hz, 6-H), 
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4.14 (s, 1.5H, CH2CONHOH, Z-isomer), 4.44 (s, 0.4H, CH2CONHOH, E-isomer), 8.87 (s, 0.7H, 
CONHOH, Z- isomer), 9.28 (s, 0.2H, CONHOH, E- isomer), 10.15 (s, 0.2H, CONHOH, E- 
isomer), 10.55 (s, 0.7H, CONHOH, Z- isomer);    13C NMR (100 MHz , DMSO-d6 )  δ 26.7 (5΄-C), 
26.9 (7΄-C), 31.9 (1΄, 3΄-C), 32.0 (4΄, 9΄-C), 32.8 (8΄, 10΄-C), 37.8 (6΄-C), 39.2 (CH2COΝΗΟH, Ζ-
isomer), 39.6 (CH2COΝΗΟH, Ε-isomer), 44.0 (6-C), 59.5 (2,2΄-C),  164.2(COΝΗΟH, Ζ-isomer), 
169.6 (COΝΗΟH, Ε-isomer), 172.3, 174.6 (3, 5-C). Anal. (C15H21N3O4) C, H, N. The 
hydrochloride salt (7a.HCl) was prepared by treating an ethanolic solution of 7a with ethereal HCl 
under ice cooling, and was fully precipitated by adding ether. The white solid was collected by 
filtration, triturated with ether, and dried in vacuo. Mp 219-222 oC (dec); Anal. (C15H22ClN3O4) C, 
H, N. 
N-Hydroxy-1-methyl-3,5-dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetamide 
(7b) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 42 gave the title compound 7b as a white crystalline solid (80%): mp 190-192ο C 
(EtOH-Et2O);  1H NMR (400 MHz , DMSO-d6) δ1.42 (d, 1H, J=10.4 Hz, 4΄e-H),1.49 (d, 1H, 
J=10.6 Hz, 9΄e-H), 1.55-1.74 (m, 5H,  6΄, 8΄, 10΄e-H), 1.78 (s, 2H, 5΄, 7΄-H), 2.02-2.20 (m, 4H, 1΄, 
3΄, 4΄a, 9΄a-H), 2.31, 2.33 (s+s, 3H, CH3),  2.68 (d, 1H, J=12.0 Hz, 10΄a-H), 3.44-3.97 (q, 2H, AB, 
JAB=19.1 Hz, 6-H), 4.07-4.25 (q, 1.5H, AB, JAB=15.5Hz,  CH2CONHOH, Z-isomer), 4.39-4.53 (q, 
0.5H, AB, JAB=16.9 Hz, CH2CONHOH, E-isomer), 8.87 (s, 0.7H, CONHOH, Z-isomer), 9.30 (s, 
0.2H, CONHOH, E-isomer), 10.17 (s, 0.2H, CONHOH, E-isomer), 10.63 (s, 0.7H, CONHOH, Z-
isomer); 13C NMR (100 MHz , DMSO-d6)  δ25.9 (5΄-C), 26.7 (7΄-C), 30.0 (1΄-C), 31.6 (3΄-C), 31.7 
(4΄-C), 31.8 (9΄-C), 32.7 (8΄-C), 33.4 (10΄-C), 36.7 (CH3), 37.3 (6΄-C), 38.9 (CH2COΝΗΟH, Ζ-
isomer), 39.7 (CH2COΝΗΟH, Ε- isomer), 52.6 (6-C), 64.8 (2,2΄-C),  164.1 (COΝΗΟH, Ζ-isomer), 
169.5 (COΝΗΟH, Ε-isomer), 170.7, 173.8 (3, 5-C); Anal. (C16H23N3O4) C, H, N. The 
hydrochloride salt (7b.HCl) was prepared as described for 7a.HCl. Mp 215-218 oC (dec). Anal. 
(C16H24ClN3O4) C, H, N. 
 
(S)-N-Hydroxy-6-methyl-3,5-dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-
acetamide (7c) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 33 provided the title compound 7c as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent upon drying at 62-64 oC under vacuum 
(10-3 mmHg) in an Abderhalden apparatus gave 7c as a light yellow crystalline solid (91%): mp 
88–91 oC;     1H NMR (600 MHz , DMSO-d6) δ1.25 (d, 3H, J=13.8 Hz,  CH3), 1.38 (d, 1H, J=12.1 
Hz, 9΄e-H), 1.47 (d, 1H, J=11.7 Hz, 4΄e-H), 1.55-1.72 (m, 5H, 6΄, 8΄, 10΄e-H), 1.76 (s, 1H,  7΄-H), 
1.79 (s, 1H, 5΄-H), 1.85 (s, 1H, 3΄-H), 2.08 (s, 1H, 1΄-H), 2.16 (d, 1H, J=11.8Hz, 4΄a-H), 2.44 (d, 
1H, J=12.0Hz, 9΄a-H), 2.84 (d, 2H, J=11.2 Hz, 1, 10΄a -H), 3.55-3.66 (sym m, 1H, 6-H),  4.09-4.16 
(q, 1.5H, AB, JAB=15.4 Hz, CH2CONHOH, Z-isomer), 4.38-4.48 (q, 0.5H, AB, JAB=16.4 Hz, 
CH2CONHOH, E-isomer), 8.82 (s,  0.6H, CONHOH, Z-isomer), 9.24 (s, 0.2H, CONHOH, E-
isomer), 10.10 (s, 0.2H, CONHOH, E-isomer), 10.50 (s, 0.5H, CONHOH, Z-isomer); 13C NMR 
(100 MHz , DMSO-d6)  δ17.9, 18.0 (CH3),  26.6 (5΄-C), 26.8 (7΄-C), 30.1, 30.3 (1΄-C), 31.1 (4΄-C), 
32.1 (8΄-C), 32.6 (9΄-C), 33.4 (10΄-C), 33.7, 33.8 (3΄-C),  37.7 (6΄-C), 39.4 (CH2COΝΗΟH, Ζ-
isomer), 39.8 (CH2COΝΗΟH, Ε-isomer), 48.6 (6-C), 60.0 (2,2΄-C),  164.1 (COΝΗΟH, Ζ-isomer), 
169.5 (COΝΗΟH, Ε-isomer), 174.6 , 174.8 (3 , 5-C); [α]23589  -20 (c 0.2, CHCl3); CΙ+ MS:  m/z: 
322.2 ([M+H]+, 7), 306.2 ([M-CH3]+, 37), 278.2 (100); HRMS (ESI): [Μ+Η]+ calcd for 
C16H24N3O4 , 322.1761, found 322.1739. The hydrochloride salt (7c.HCl) was prepared by treating 
an ether solution of 7c with ethereal HCl under ice cooling. The white precipitate was collected by 
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filtration, triturated with ether, and dried in vacuo. Mp 178-180 oC (dec). Anal. (C16H24ClN3O4) C, 
H, N.   
 (S)-N-Hydroxy-3,5-dioxo-6-(phenylmethyl)spiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-
acetamide (7d) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 34 provided the title compound 7d as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent as described for 7c gave 7d as a pale 
yellow crystalline solid (95%): mp 97 – 100 oC; 1H NMR (400 MHz, DMSO-d6) δ1.29 (d, 2H, 
J=11.5 Hz, 4΄e, 9΄e-H), 1.41-1.73 (complex m, 7H, 4΄a, 6΄, 7΄, 8΄, 10΄e-H), 1.76 (s, 1H, 5΄-H), 1.82 
(s, 1H, 3΄-H), 2.05 (s, 1H, 1΄-H), 2.17 (d, 1H, J=11.4 Hz, 9΄a-H), 2.66-2.90 (complex m, 3H, 
CHAHMPh, 1, 10΄a-H), 3.32 (dd, 1H, AMX, M region, JAM=13.8 Hz, JMX= 2.8 Hz, CHAHMPh), 3.73 
(td, 1H, J=3.3 Hz, 10.7 Hz,  6-Hx), 4.17 (s, 1.6H, CH2CONHOH, Z-isomer), 4.42-4.52 (q, AB, 0,4 
H, JAB=16.8 Hz,  CH2CONHOH, E- isomer), 7.16-7.23 (m, 1H, 4-aromatic H), 7.24-7.36 (m, 4Η, 
2, 3, 5, 6-aromatic Η),  8.88 (s, 0,7H, CONHOΗ, Ζ- isomer), 9.30 (s, 0,2H, CONHOΗ, E-isomer), 
10.16 (s, 0,2H, CONHOΗ, E- isomer), 10.56 (s, 0,7H, CONHOΗ, Z- isomer); 13C NMR (100 
MHz, DMSO-d6) δ26.5 (5΄-C), 26.7 (7΄-C), 29.9, 30.0 (1΄-C), 30.8 (4΄-C), 32.0 (9΄-C), 32.7 (8΄-C), 
33.3 (10΄-C), 34.0, 34.1 (3΄-C), 37.3 (CH2Ph), 37.7 (6΄-C), 39.6 (CH2COΝHOH, Ζ-isomer), 39.9 
(CH2COΝHOH, E-isomer), 54.26, 54.33 (6-C),  59.85, 59.93 (2,2΄-C), 126.2 (4-aromatic C), 
128.0, 129.0 (2, 3, 5, 6- aromatic C), 138.6 (1- aromatic C), 164.1 (CONHOΗ, Ζ-isomer), 169.5 
(CONHOΗ, E-isomer), 173.7, 174.5 (3, 5-C); [α]25589  -60 (c 0,2, CHCl3); CI+ MS: m/z  398.2 
([M+H]+, 100), 306.1 ([M- CH2Ph] +, 57); HRMS (ESI): [M+H]+ calcd. for C22H28N3O4, 398.2074, 
found 398.2059. The hydrochloride salt (7d.HCl) was prepared as described for 7c.HCl. Mp 143-
146 oC (dec); Anal. (C22H28ClN3O4) C, H, N. 
(R)-N-Hydroxy-3,5-dioxo-6-(phenylmethyl)spiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-
acetamide (7e) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 35 provided the title compound 7e as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent as described for 7c gave 7e as a light 
yellow crystalline solid (95%): mp 96–98 oC; NMR spectroscopic data of this compound are 
identical to that of 7d; [α]25589 +59 (c 0.2, CHCl3); EΙ MS:  m/z 397.2 ([M]+, 7), 307,2 ([M+H- 
CH2Ph]+, 17), 306 ([M-CH2Ph]+, 100); HRMS (ESI): [Μ+Η]+ calcd for C22H28N3O4, 398.2074, 
found 398.2064. The hydrochloride salt (7e.HCl) was prepared as described for 7c.HCl. Mp 142-
145 oC (dec). Anal. (C22H28ClN3O4) C, H, N.   
(R,S)-N-Hydroxy-3,5-dioxo-6-(phenylmethyl)spiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-
4-acetamide (8) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 36 provided the title compound 8 as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent as described for 7c gave 8 as a light 
yellow crystalline solid (96%): mp 90–92 oC. NMR spectroscopic data of this compound are 
identical to that of 7d; CΙ+ MS: m/z 398.3 ([M+H] +, 100), 306,2 ([M-CH2Ph]+, 61); HRMS (ESI): 
[Μ+Η]+ calcd for C22H28N3O4, 398.2074, found 398.2025. The hydrochloride salt (8.HCl) was 
prepared as described for 7c.HCl. Mp 135-138 oC (dec). Anal. (C22H28ClN3O4) C, H, N. 
N-Hydroxy-3,5-dioxo-1,4-diazaspiro[5.7]tridecane-4-acetamide (9a) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 60 provided the title compound 9a as a white foamy solid, which strongly binds the 
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eluting solvent (AcOEt, MeOH). Removal of the entrapped solvents as described for 7c gave 9a as 
a pale yellow solid (90%): mp 148–151 oC; 1H NMR (600 MHz, DMSO-d6) δ1.50 (br s, 8H, 8, 9, 
10, 11, 12-Η), 1.58-1.70 (m, 4H, 7, 9, 11, 13-Η), 1.95-1.99 (q, 2H, J=6.7, 9.2 Hz,  7, 13-Η), 2.98 (t, 
1H, J=8.5 Hz, 1-H) 3.57 (d, 2Η, J=7.9 Hz, 2-H), 4.13 (s, 1.5H, CH2CONHOH, Z-isomer), 4.42 (s, 
0.4H,  CH2CONHOH, E-isomer), 8.86 (s, 0.7H, CONHOH, Z-isomer), 9.27 (s, 0.2H, CONHOH, 
E-isomer), 10.15 (s, 0.2H, CONHOH, E-isomer), 10.52 (s, 0.7H, CONHOH, Z-isomer); 13C NMR 
(100 MHz, DMSO-d6) δ20.9 (9, 11-C), 24.4 (10-C), 27.7 (8, 12-C), 30.2 (7, 13-C), 38.6 
(CH2CONHOH, Z-isomer), 38.8 (CH2CONHOH, E-isomer),  44.7 (2-C), 58.9 (6-C), 163.9 
(CONHOH, Z-isomer), 169.3 (CONHOH, E-isomer), 171.5, 176.3 (3, 5-C); CΙ+ MS:  m/z: 284.2 
([M+H]+, 11), 268,2 (46), 240.2(100), 222.2 (72), 195 (70); HRMS (ESI): [Μ+Η]+ calcd for 
C13H22N3O4, 284.1605, found 284.1586. The hydrochloride salt (9a.HCl) was prepared as 
described for 7a.HCl. Mp 179-182 oC. Anal. (C13H22ClN3O4) C, H, N. 
N-Hydroxy-1-methyl-3,5-dioxo-1,4-diazaspiro[5.7]tridecane-4-acetamide (9b) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 72 provided the title compound 9b as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent as described for 7c gave 9b as a white 
crystalline solid (90%): mp 160–163 oC; 1H NMR (400 MHz, DMSO-d6) δ1.33-1.63 (m, 8H, 8, 9, 
10, 11, 12-Η), 1.65-1.87 (m, 4H, 7, 9, 11, 13-Η), 1.89-2.04 (m, 2H, 7, 13-Η), 2.36 (s, 2.2H, CH3, 
Z-isomer), 2.38 (s, 0.9H, CH3, E-isomer),  3.73 (s, 2H, 2-H), 4.16 (s, 1.5H, CH2CONHOH, Z-
isomer), 4.46 (s, 0.5H,  CH2CONHOH, E-isomer), 8.88 (s, 0.8H, CONHOH, Z-isomer), 9.30 (br s, 
0.3H, CONHOH, E-isomer), 10.18 (s, 0.3H, CONHOH, E-isomer), 10.63 (s, 0.7H, CONHOH, Z-
isomer); 13C NMR (100 MHz, DMSO-d6) δ20.4 (9, 11-C), 24.3 (10-C), 27.5 (8, 12-C), 29.3 (7, 13-
C), 38.1 (CH2CONHOH, Z-isomer), 38.5, 38.6 (CH3),  38.9 (CH2CONHOH, E-isomer),  53.7 (2-
C), 63.7 (6-C), 164.0 (CONHOH, Z-isomer), 169.3 (CONHOH, E-isomer), 170.0, 175.5 (3, 5-C); 
CΙ+ MS:  m/z: 298.2 ([M+H]+, 7), 282,2 ([M–CH3]+, 77), 281.2(26), 254.2(100), 236.2(89), 
209.2(100); HRMS (ESI): [Μ+Η]+ calcd for C14H24N3O4, 298.1761, found 298.1738. The 
hydrochloride salt (9b.HCl) was prepared as described for 7a.HCl. Mp 163-165 oC (dec). Anal. 
(C14H24ClN3O4) C, H, N. 
 
(S)-N-Hydroxy-2-methyl-3,5-dioxo-1,4-diazaspiro[5.7]tridecane-4-acetamide (9c) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 61 provided the title compound 9c as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent as described for 7c gave 9c as a white 
crystalline solid (90%): mp 82–85 oC; 1H NMR (400 MHz, DMSO-d6) δ(ppm): 1.28 (d, 3H, 
J=6.8Hz, CH3), 1.35-1.95 (complex m, 13H, 7, 8, 9, 10, 11, 12, 13-Η), 2.07-2.13 (sym q, 1H, J=9,2 
Hz, 13-Η), 2.72 (br d, 1H, J=8,3 Hz, 1-H), 3.66 (~br t, 1H, J=6-7 Hz,  2-H), 4.07-4.16 (q, AB, 
1.5H, JAB=15.2 Hz, CH2CONHOH, Z-isomer), 4.41 (s, 0.4H,  CH2CONHOH, E-isomer), 8.85 (s, 
0.8H, CONHOH, Z-isomer), 9.26 (s, 0.2H, CONHOH, E-isomer), 10.13 (s, 0.2H, CONHOH, E-
isomer), 10.51 (s, 0.8H, CONHOH, Z-isomer); 13C NMR (100 MHz, DMSO-d6) δ17.0 (CH3), 20.8 
(9-C), 21.2 (11-C), 24.5 (10-C), 26.9 (8-C), 27.8 (7-C), 28.5 (12-C), 33.3 (13-C), 39.1 
(CH2CONHOH, Z-isomer), 39.2 (CH2CONHOH, E-isomer),  48.8 (2-C), 59.8 (6-C), 163.9 
(CONHOH, Z-isomer), 169.3 (CONHOH, E-isomer), 173.8, 176.6 (3, 5-C); [α]26589 +12 (c 0.1, 
CHCl3); EI  MS:  m/z   297.2([M]+, 11), 269,1([M–H2O]+, 61), 264.1(52), 209.2(53); HRMS (ESI): 
[Μ+Η]+ calcd for C14H24N3O4, 298.1767, found 298.1744. The hydrochloride salt (9c.HCl) was 
prepared as described for 7c.HCl. Mp 170-172 oC (dec). Anal. (C14H24Cl N3O4) C, H, N.   
(S)-N-Hydroxy-3,5-dioxo-2-(phenylmethyl)-1,4-diazaspiro[5.7]tridecane-4-acetamide (9d) 
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Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 62 provided the title compound 9d as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent upon drying at 50-55 oC under vacuum 
(10-3 mmHg) in an Abderhalden apparatus gave 9d as a white crystalline solid (98%): mp 65–68 
oC; 1H NMR (400 MHz, DMSO-d6) δ1.18-1.67 (m, 11H, 7, 8, 9, 10, 11, 12, 13-Η), 1.69-1.82 (m, 
2H, 7, 12-Η), 2.0-2.12 (m, 1H, 13-Η), 2.56-2.65 (m, 1H, 1-H), 2.68-2.82 (m, 1H, AMX, A region, 
CHAHMPh), 3.32 (dd under DMSO water peak, 1H, AMX, M region, JMX=3.6 Hz, CHAHMPh), 
3.75-3.86 (m, 1H, AMX, X region, 2-Hx), 4.09-4.18 (q, AB, 1.6H, JAB=15.6 Hz, CH2CONHOH, 
Z-isomer), 4.42 (s, 0.4H,  CH2CONHOH, E-isomer), 7.14-7.22 (m, 1H, 4-aromatic H), 7.23-7.33 
(m, 4Η, 2,3,5,6-aromatic Η), 8.85(s, 0.7H, CONHOH, Z-isomer), 9.27 (s, 0.2H, CONHOH, E-
isomer), 10.15(s, 0.2H, CONHOH, E-isomer), 10.51 (s, 0.7H, CONHOH, Z-isomer); 13C NMR 
(100 MHz, DMSO-d6) δ20.3 (9-C), 21.1 (11-C), 24.2 (10-C), 26.7 (8-C), 27.5 (7-C), 28.3 (12-C), 
33.8 (13-C), 36.2 (CH2Ph), 39.2 (CH2CONHOH), 54.3 (2-C), 59.6 (6-C), 126.0 (4-aromatic C), 
127.9, 129.0 (2, 3, 5, 6-aromatic C), 138.7 (1-aromatic C), 163.9 (CONHOH, Z-isomer), 169.3 
(CONHOH, E-isomer), 172.9, 176.6 (3, 5-C); [α]21589 -16 (C 0.2, CHCl3) ; EI  MS:  m/z   
373.1([M]+, 4), 282,1([M–CH2Ph]+, 100); HRMS (ESI): [Μ+Η]+ calcd for C20H28N3O4, 374.2069, 
found 374.2047. The hydrochloride salt (9d.HCl) was prepared as described for 7c.HCl. Mp 202-
205 oC (dec). Anal. (C20H28Cl N3O4) C, H, N. 
N-Hydroxy-3,5-dioxo-1,4-diazaspiro[5.6]dodecane-4-acetamide (10a) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 63 provided the title compound 10a as a white foamy solid, which strongly binds the 
eluting solvent (AcOEt). Removal of the entrapped solvent as described for 7c gave 10a as a pale 
yellow crystalline solid (90%): mp 142–144 oC (dec); 1H NMR (400 MHz, DMSO-d6) δ1.40-1.76 
(m, 10H, 7, 8, 9, 10, 11, 12-H), 1.82-1.97 (m, 2H,  7, 12-H), 3.01 (br s, 1H, 1-H), 3.56 (d, 2H, 
J=6.4 Hz, 2-H), 4.13 (s, 1.6H, CH2CONHOH, Ζ-isomer), 4.42 (s, 0.4H, CH2CONHOH, E-isomer), 
8.87 (s, 0.7H, CONHOH
 , Z-isomer), 9.27 (s, 0.2H, CONHOH , E-isomer), 10.15 (s, 0.2H, 
CONHOH, E-isomer), 10.53 (s, 0.7H, CONHOH, Ζ-isomer); 13C NMR (100 MHz, , DMSO-d6) 
δ21.7(8, 11-C), 29.4, 29.5 (9, 10-C), 35.1 (7, 12-C),   38.7(CH2CONHOH, Ζ-isomer), 38.9 
(CH2CONHOH, E-isomer) 44.7 (2-C), 59.6, 59.7 (6-C), 163.9 (CONHOH, Ζ-isomer), 169.3 
(CONHOH, E-isomer), 171.5, 176.9 (3, 5-C); CΙ+ MS:  m/z 270.2([M+H]+, 18), 252,1([M+H–
H2O]+, 24), 226.2(86), 209.1(96), 208.1(100); HRMS (ESI): [Μ+Η]+ calcd for C12H20N3O4, 
270.1448, found 270.1434. The hydrochloride salt (10a.HCl) was prepared as described for 
7a.HCl. Mp 190-192 oC (dec). Anal. (C12H20ClN3O4) C, H, N.   
N-Hydroxy-1-methyl-3,5-dioxo-1,4-diazaspiro[5.6]dodecane-4-acetamide (10b) 
Following the general hydrogenolysis procedure described in the main manuscript, O-benzyl 
hydroxamate 73 provided the title compound 10b as a white crystalline solid, which strongly binds 
the eluting solvent (AcOEt). Removal of the entrapped solvent upon drying at 40 oC under vacuum 
(10-3 mmHg) in an Abderhalden apparatus gave 10b as a glass solid (93%): 1H NMR (400 MHz, 
DMSO-d6) δ1.46-1.65 (br s, 8H, 8, 9, 10, 11-H), 1.78-2.0 (m, 4H,  7, 12-H), 2.37 (s, 2.2H, CH3, Ζ-
isomer), 2.39 (s, 0.8H, CH3, E-isomer), 3.72 (s, 2H, 2-H), 4.16 (s, 1.4H, CH2CONHOH, Ζ-isomer), 
4.46 (s, 0.5H, CH2CONHOH, E-isomer), 8.87 (s, 0.7H, CONHOH , Z-isomer), 9.29 (s, 0.2H, 
CONHOH
 , E-isomer), 10.17 (s, 0.2H, CONHOH, E-isomer), 10.62 (s, 0.7H, CONHOH, Ζ-
isomer); 13C NMR (100 MHz, , DMSO-d6) δ21.6 (8, 11-C), 28.7 (9, 10-C), 33.4 (7, 12-C),   38.16, 
38.21 (CH3), 38.3 (CH2CONHOH, Ζ-isomer), 39.0 (CH2CONHOH, E-isomer), 53.7 (2-C), 64.6 
(6-C), 163.9 (CONHOH, Ζ-isomer), 169.3 (CONHOH, E-isomer), 170.0, 175.4, 175.5 (3, 5-C); 
CΙ+ MS:  m/z: 284.2 ([M+H]+, 100), 283,2 ([M]+, 21), 256.2(86); HRMS (ESI): [Μ+Η]+ calcd for 
C13H22N3O4, 284.1610, found 284.1573. The hydrochloride salt (10b.HCl) was prepared as 
described for 7c.HCl. Mp 132-136 oC (slightly hydroscopic). Anal. (C13H22ClN3O4) C, H, N.   
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3,5-Dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetamide (43) 
Using a procedure essentially similar to that described earlier for the preparation of compound 
22,9 the amide ester precursor 17 (365 mg, 1.3 mmol) was treated with (CH3)3SiNK (259 mg, 1.3 
mmol), and the 2,6-DKP imidic potassium salt formed was subsequently reacted with 
bromoacetamide (190 mg, 1.37 mmol). The reaction mixture was then poured onto cold brine 
and quenched as in 22. The resulting residue was chromatographed on a silica gel column eluting 
first with AcOEt-Et2O 1:1 and then AcOEt to give the title compound 43 as a white solid (191 
mg, 50%): mp 168–1690 C (EtOH – Et2O); 1H NMR (600 MHz, DMSO-d6) δ1.43 (d, 2H, J=12.0 
Hz, 4΄e, 9΄e-H), 1.57-1.69 (m, 4H, 6΄, 8΄e, 10΄e-H), 1.75 (s, 1H, 7΄-H ), 1.79 (s, 1H, 5΄-Η), 1.95 
(s, 2H, 1΄, 3΄-Η), 2.17-2.32 (m, 4H, 4΄a, 8΄a, 9΄a, 10΄a-H), 3.09 (br s, 1H, 1-H), 3.56 (d, 2H, 
J=6.5 Hz, 6-H), 4.17 (s, 2H, CH2CONH2), 6.99 (s, 1H, CONHH), 7.38 (s, 1H, CONHH); 13C 
NMR (100 MHz, DMSO-d6) δ26.6 (5΄-C), 26.8 (7΄-C), 31.8 (1΄, 3΄-C), 31.9 (4΄, 9΄-C), 32.7 (8΄, 
10΄-C), 37.7 (6΄-C), 41.4 (CH2CONH2), 43.9 (6-C), 59.3 (2, 2΄-C), 168.5(CONH2), 172.1, 174.5 
(3, 5-C). Anal.  (C15H21N3O3) C, H, N.  
3,5-Dioxo-N-(phenylmethoxy)spiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetamide 
(32) 
To a solution of the carboxylic acid 279 (320 mg, 1.1 mmol) in dry THF (15mL) was added 
1,1΄-carbonyldiimidazole (214 mg, 1.32 mmol), and the mixture was stirred at 28 oC for 1h under 
argon. Then, O-benzylhydroxylamine hydrochloride (210 mg, 1.32 mmol) and triethylamine 
(202 mg, 2 mmol) were added successively, and the stirring was continued at 28 oC for 24h and 
then at 45 oC for 1h under argon. After removal of the solvent in vacuo, water (20 mL) was 
added, and the mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were 
washed with brine (2x20 mL) dried (Na2SO4) and evaporated in vacuo. The viscous oily residue 
was purified by column chromatography on silica gel eluting first with Et2O-n-hexane 2:1 and 
then AcOEt to give the corresponding O-benzyl hydroxamate 32 as a white solid (312 mg, 72%): 
mp 162-164 οC (AcOEt); 1H NMR (400 MHz , CDCl3 , 270K) δ 1.50 (d, 2H, J=12.5 Hz, 4΄e, 9΄e-
H), 1.62-1.75 (m, 4H, 6΄, 8΄e, 10΄e-H), 1.82 (s, 1H, 7΄-H), 1.86 (s, 1H, 5΄-H), 1.94 (s, 1H, 1΄-H), 
1.99 (s, 1H, 3΄-H),  1.90-2.08 (br s, 1H, 1-H), 2.23 (br s, 4H,  4΄a, 8΄a, 9΄a, 10΄a-H), 3.68, 3.72 
(s+s, 2H, 6-H), 4.23 (s, 0.99H, CH2CONHOCH2Ph, Ζ-isomer), 4.59 (s, 0.94H,   
CH2CONHOCH2Ph, Ε-isomer), 4.84, 4.88 (s+s, 2H, CONHOCH2Ph), 7.37 (br s, 5H, aromatic–
Η), 8.34 (s, 0.4H, CONHOCH2Ph, Ε-isomer), 8.89 (s, 0.5H, CONHOCH2Ph, Ζ-isomer); 13C 
NMR (100 MHz , CDCl3  ,270K)  δ26.8 (5΄-C), 27.0 (7΄-C), 32.1 (4΄, 9΄-C), 32.3 (1΄, 3΄-C), 33.0 
(8΄, 10΄-C), 37.7 (6΄-C), 39.8, 39.9 (CH2COΝΗΟCH2Ph), 44.2 (6-C), 60.3, 60.4(2,2΄-C), 78.1, 
79.4 (COΝΗΟCH2Ph),  128.5 , 128.8, 129.1, 129.3, 129.4 (2, 3, 4, 5, 6-aromatic C), 133.9, 134.9 
(1-aromatic C), 165.4 (COΝΗΟCH2Ph, Ζ-isomer), 170.5 (COΝΗΟCH2Ph, E-isomer), 172.4, 
172.5, 174.5, 174.6 (3, 5-C). Anal (C22H27N3O4) C, H, N. 
3,5-Dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetohydrazide (44) 
Carboxylic acid 279 (585 mg, 2.0 mmol) was treated with 1,1΄-carbonyldiimidazole (390 mg, 2.4 
mmol) in dry THF (26 mL) as described in 32. To the solution was then added benzylcarbazate 
(399 mg, 2.4 mmol), and the reaction mixture was stirred at 28 oC for 25h under argon. After 
removal of the solvent in vacuo, the residue was dissolved in chloroform, and the resulting solution 
washed with brine (2x30 mL), dried (Na2SO4), and evaporated. The residue was purified by 
column chromatography on silica gel eluting first with AcOEt-n-hexane 1:1 and then AcOEt to 
give a white foamy solid (700 mg): EI MS m/z 440.4 ([M]+, 7). This was then dissolved in EtOH 
(55 mL), and the solution was hydrogenated as described for the preparation of 7a-e, 8, 9a-d, 10a, 
and 10b to yield the acetohydrazide 44 as a TLC and 1H NMR pure white solid (466 mg, 76% 
from 27), which was recrystalized from EtOH-Et2O: mp 197 – 2000 C (dec); 1H NMR (600 MHz, 
DMSO-d6) δ1.43 (d, 2H, J=11.9 Hz, 4΄e, 9΄e-H), 1.58-1.72 (m, 4H, 6΄, 8΄e, 10΄e-H), 1.75 (s, 1H, 
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7΄-H ), 1.79 (s, 1H, 5΄-Η), 1.90-2.0 (s, 2H, 1΄, 3΄-Η), 2.26 (~t, 4H, J=11.9, 12.8 Hz, 4΄a, 8΄a, 9΄a, 
10΄a-H), 3.13 (~br s, 1H, 1-H), 3.56 (d, 2H, J=7.0 Hz, 6-H), 3.92-4.75 (v br s, 2H, CONHNH2), 
4.18 (s, 1.7H, CH2CONHNH2, Z-isomer), 4.52 (s, 0.2Η, CH2CONHNH2, E-isomer),  8.46 (s, 0.1H, 
CONHNH2, E-isomer), 9.06 (s, 0.8H, CONHNH2, Z-isomer); 13C NMR (100 MHz, DMSO-d6) 
δ26.6 (5΄-C), 26.9 (7΄-C), 31.8 (1΄, 3΄-C), 31.9 (4΄, 9΄-C), 32.7 (8΄, 10΄-C), 37.7 (6΄-C), 39.95, 
40.02 (CH2CONHNH2),  44.0 (6-C), 59.4 (2, 2΄-C), 166.5 (CONHNH2), 172.2, 172.3, 174.5, 174.7 
(3, 5-C). Anal.  (C15H22N4O3) C, H, N. 
N-Methoxy-3,5-dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetamide (45) 
Prepared from carboxylic acid 279 in exactly the same procedure described in 32 except that O-
methyl hydroxylamine hydrochloride was used. The resulting oily residue was chromatographed 
on silica gel column using AcOEt-Et2O 1:1 to afford colourless viscous oil which strongly binds 
the aforementioned solvents. Removal of the entrapped solvents upon drying at 50 oC under 
vacuum (10-3 mmHg) in an Abderhalden apparatus gave the title compound 45 as a glass solid: 
(82%); 1H NMR (400 MHz, CDCl3) δ1.51 (d, 2H, J=12.3 Hz, 4΄e, 9΄e-H), 1.63-1.77 (m, 4H, 6΄, 
8΄e, 10΄e-H), 1.82 (s, 1H, 7΄-H ), 1.86 (s, 1H, 5΄-Η), 1.92-2.10 (br s, 3H, 1, 1΄, 3΄-Η), 2.27 (d, 4H, 
J=11.8 Hz, 4΄a, 8΄a, 9΄a, 10΄a-H), 3.60-3.88 (br s, 5H, CONHOCH3, 6-H), 4.27 (br s, 1.1H, 
CH2CONHOCH3, Z-isomer), 4.63 (br s, 0.7Η, CH2CONHOCH3, E-isomer),  8.97(br s, 0.3H, 
CONHOCH3, E-isomer), 9.67 (br s, 0.6H, CONHOCH3, Z-isomer); 13C NMR (100 MHz, CDCl3) 
δ27.0 (5΄-C), 27.2 (7΄-C), 32.2 (4΄, 9΄-C) 32.5 (1΄, 3΄-C), 33.1 (8΄, 10΄-C), 37.9 (6΄-C), 39.8 
(CH2CONHOCH3), 44.4 (6-C), 60.4 (2,2΄-C), 64.3, 65.1 (CONHOCH3),  165.6 (CONHOCH3, Ζ-
isomer), 170.6 (CONHOCH3, Ε-isomer),  172.6, 174.6 (3, 5-C); CΙ+ MS: m/z 322.2 ([M+H]+, 24), 
290.2 ([M-OCH3]+, 15), 294.2 (64), 219.1 (79). The hydrochloride salt (45.HCl) was prepared by 
treating a solution of 45 in Et2O-AcOEt 3:2 with ethereal HCl under ice cooling. The white solid 
was collected by filtration, triturated with Et2O and dried at 62-64 oC under vacuum (10-3 mmHg). 
Mp 193-195 oC; Anal.  (C16H24ClN3O4 0.4Et2O) C, H, N. 
Ν–[2–Cyano(tricyclo[3.3.1.13,7]dec–2–yl)]–L–phenylalanine methyl ester (14) 
Prepared by employing the Strecker reaction on the adamantanone 11 in exactly the same 
procedure described earlier for the preparation of compound 12,9 except that methyl L-
phenylalaninate hydrochloride was used. The resulting off-white solid was purified by column 
chromatography on silica gel eluting first with Et2O-n-hexane 1:2 and then 1:1 to afford the title 
compound 14  as a white crystalline solid (89%): mp 78-80 oC (Et2O-n-pentane); 1H NMR (400 
MHz, CDCl3) δ1.15 (dd, 1H, J=2.5, 12.4 Hz, 4e-Ad H), 1.40 (dd, 1H, J=2.4, 12.7 Hz, 9e-Ad H), 
1.48-1.62 (complex m, 4H, 4a, 5, 6-Ad H), 1.64-1.88 (complex m, 6H, 1, 3, 7, 8e, 10e-Ad H, NH), 
1.98 (d, 1H, J=13.4 Hz, 8a-Ad H), 2.03-2.13 (m, 2H, 9a, 10a-Ad H), 2.76-2.81 (q, 1H, AMX, A 
region, JAM=13.4 Hz, JAX=8.0 Hz, NH-CHX-CHAHMPh), 2.92-2.97 (q, 1H, AMX, M region, 
JAM=13.4 Hz, JMX=5.6 Hz, NH-CHX-CHAHMPh), 3.58-3.62 (q, 1H, AMX, X region, JAX=8.0 Hz, 
JMX=5.6 Hz, NH-CHX-CHAHMPh), 3.64 (s, 3H, CH3), 7.09-7.24 (m, 5H, aromatic Η); 13C NMR 
(100 MHz, CDCl3) δ(ppm):26.4 (5-Ad C), 26.6 (7-Ad C), 29.6 (4-Ad C), 30.4 (9-Ad C), 33.4 (1-
Ad C), 34.1 (8-Ad C), 34.7 (10-Ad C), 36.5 (3-Ad C), 37.4 (6-Ad C), 40.8 (CH2Ph), 51.8 (CH3), 
57.7 (HN-CH), 60.7 (2-Ad C), 121.9 (CN), 126.7, 128.2, 129.5 (2, 3, 4, 5, 6-aromatic C), 137.1 (1-
aromatic C), 174.8 (CO2CH3); [α]25589= -6 (c 0.2, AcOEt). Anal.  (C21H26N2O2) C, H, N. 
Ν–[2–Aminocarbonyl(tricyclo[3.3.1.13,7]dec–2–yl)]–L–phenylalanine methyl ester (19) 
To a vigorous stirred solution of the aminonitrile 14 (1.93 g, 5.7 mmol) in CH2Cl2 (24 mL) 
was added dropwise H2SO4 97% (9.5 mL), and the mixture was vigorously stirred at room 
temperature for 48 h. The reaction mixture was then poured onto ice (30 g) and neutralized with 
aqueous NH3 26 % under ice cooling. The organic layer was separated, and the aqueous layer 
was extracted with CH2Cl2 (3x30 mL). The combined organic phase was washed with water (30 
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mL) and brine (30 mL), dried (Na2SO4), and evaporated. The resulted coloured residue was 
purified by column chromatography on silica gel using AcOEt-Et2O 1:1 to afford the title 
compound 19 as a white crystalline solid (1.04 g, 51%): mp 141-143 0C (CH2Cl2-Et2O); 1Η 
NMR (400 MHz, CDCl3) δ1.27 (~d, 1H, J=11.7 Hz, 4e-Ad H), 1.39 (~d, 1H, J=11.7 Hz, 9e-Ad 
H), 1.47-1.73 (complex m, 8H, 4a, 5, 6, 7, 8, 10e-Ad H), 1.74-1.92 (m, 3H, NH, 3, 10a-Ad H), 
1.95 (s, 1H, 1-Ad H), 2.12 (d, 1H, J=12.6 Hz, 9a-Ad H), 2.67-2.72 (q, 1H, AMX, A region, 
JAM=13.2 Hz, JAX=7.8 Hz, NH-CHX-CHAHMPh), 2.80-2.85 (q, 1H, AMX, M region, JAM=13.2 
Hz, JMX=5.7 Hz, NH-CHX-CHAHMPh), 3.53 (br s, 4H, CH3, NH-CHX-CHAHMPh), 5.50 (br s, 2H, 
CONH2), 7.05-7.22 (m, 5H, aromatic Η); 13C NMR (100 MHz, CDCl3) δ26.7 (5-Ad C), 26.9 (7-
Ad C), 31.4 (4-Ad C), 31.7 (1-Ad C), 32.1 (9-Ad C), 34.2 (3-Ad C), 34.4 (8-Ad C), 34.6 (10-Ad 
C), 37.6 (6-Ad C), 41.5 (CH2Ph), 51.4 (CH3), 56.3 (NHCH), 64.2 (2-Ad C), 126.5, 128.1, 129.6 
(2, 3, 4, 5, 6-aromatic C), 137.5 (1-aromatic C), 175.4 (CO2CH3), 176.9 (CONH2); [α]25589 +12 
(c 0.2, MeOH). Anal.  (C21H28N2O3) C, H, N.  
(S)–3,5–Dioxo–6–(phenylmethyl)spiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetic 
acid benzyl ester (24) 
Prepared from the above amide-ester precursor 19 in exactly the same procedure described 
earlier for the preparation of compound 22.9 The resulted oily residue was purified by column 
chromatography on silica gel using Et2O-n-hexane 1:1 to afford the title compound 24 as a 
colourless viscous oil (86%): 1H NMR (400 MHz, CDCl3) δ1.38 (d, 2H, J=12.9Hz, 4΄e, 9΄e-H), 
1.29-1.48 (v br s, 1H, 1-H), 1.51-1.70 (complex m, 7H, 4΄a, 6΄, 7΄, 8΄, 10΄e-H), 1.75 (br s, 2H, 3΄, 
5΄-H ), 1.95 (d, 1H, J=12.8 Hz, 9΄a-H), 2.02 (s, 1H, 1΄-H), 2.82 (d, 1H, J=12.6 Hz, 10΄a-H), 
2.92-2.97 (q, 1H, AMX, A region, JAM=13.8 Hz, JAX=8.1 Hz, 6-CHAHMPh), 3.30 (dd, 1H, AMX, 
M region, JAM=13.8 Hz, JMX=4.0 Hz, 6-CHAHMPh), 3.77-3.87 (m, 1H, AMX, X region, 6-Hx), 
4.33-4.53 (q, AB, 2H, J=16.8 Hz, CH2CO2CH2Ph), 5,07 (s, 2H, CO2CH2Ph), 7.10-7.35 (m, 10H, 
aromatic Η); 13C NMR (100 MHz, CDCl3) δ26.9 (5΄-C), 27.0 (7΄-C), 30.5 (1΄-C), 31.3 (4΄-C), 
32.4 (9΄-C), 33.2 (8΄-C), 33.9 (10΄-C), 34.8 (3΄-C), 37.8 (CH2Ph), 37.9 (6΄-C), 40.9 
(CH2CO2CH2Ph), 54.1 (6-C), 60.8 (2,2΄-C), 67.2 (CO2CH2Ph), 127.1, 128.3, 128.4, 128.6, 128.7, 
129.2, 135.1, 136.6 (aromatic C), 168.0 (CO2CH2Ph) 173.5, 174.1 (3, 5-C); [α]24589 -34 (c 0.2, 
CHCl3); CI+ MS: m/z 473.3 ([M+H]+, 50), 472.3 ([M]+, 13), 382.2 ([M+H-CH2Ph]+, 23), 381.2 
([M- CH2Ph]+, 100); HRMS (ESI): [Μ+Η]+ calcd for C29H33N2O4, 473.2440, found 473.2440.  
(S)–3,5–Dioxo–6–(phenylmethyl)spiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetic 
acid (29) 
Prepared from the above benzyl ester 24 by catalytic hydrogenolysis in EtOH-AcOEt 3:2 
following the procedure described earlier for the preparation of carboxylic acid 27.9 White 
foamy solid which strongly binds the aforementioned solvents. Removal of the entrapped 
solvents upon drying at 62-64 oC under vacuum (10-3 mmHg) in an Abderhalden apparatus gave 
the title compound 29 as a glass solid (almost quantitative yield): 1H NMR (400 MHz, CDCl3) 
δ1.35-1.47 (m, 2H, 4΄e, 9΄e-H), 1.52-1.73 (m, 7H, 4΄a, 6΄, 7΄, 8΄, 10΄e-H), 1.79(s, 2H, 3΄, 5΄-H ), 
1.95 (d, 1H, J=12.5 Hz, 9΄a-H), 2.05 (s, 1H, 1΄-H), 2.84 (d, 1H, J=12.8 Hz, 10΄a-H), 2.99-3.05 
(q, 1H, AMX, A region, JAM=13.8 Hz, JAX=8.0 Hz, CHAHMPh), 3.31 (dd, 1H, AMX, M region, 
JAM=13.8 Hz, JMX=4.1 Hz, CHAHMPh), 3.82-3.85 (q, 1H, AMX, X region, JAX=8.0 Hz, JMX=4.1 
Hz, 6-Hx), 4.35-4.51 (q, AB, 2H, JAB=17.1 Hz, CH2CO2H), 4.20-6.80 (v br s, 2H, COOH, 1-H), 
7.13-7.30 (m, 5H, aromatic Η); 13C NMR (100 MHz, CDCl3) δ26.8 (5΄-C), 26.9 (7΄-C), 30.4 (1΄-
C), 31.3 (4΄-C), 32.4 (9΄-C), 33.2 (8΄-C), 33.8 (10΄-C), 34.7 (3΄-C), 37.5 (CH2Ph), 37.9 (6΄-C), 
40.7 (CH2CO2H), 54.0 (6-C), 61.1 (2,2΄-C), 127.2, 128.8, 129.3 (2 3, 4, 5, 6-aromatic C), 136.3 
(1-aromatic C), 173.0 (CO2H), 173.5 (3, 5-C). The hydrochloride salt (29.HCl) was prepared as 
described for 7c.HCl. Mp 182-184 oC (dec); [α]25589 -24 (c 0.2, MeOH). Anal. (C22H27Cl N2O4) 
C, H, N.  
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(S)–6–(Phenylmethyl)spiro[piperazine–2,2΄–tricyclo[3.3.1.13,7]decane]–3,5–dione (37) 
Prepared from the above amide-ester precursor 19 in exactly the same procedure described 
earlier for the preparation of the diketopiperazine 6a.9 White foamy solid which strongly binds 
the eluting solvents. Removal of the entrapped solvents upon drying at 62-64 oC under vacuum 
(10-3 mmHg) gave the title compound 37 as a glass solid (96%): 1H NMR (400 MHz, CDCl3) 
δ1.39 (d, 2H, J=12.4Hz, 4΄e, 9΄e-H), 1.37-1.50 (v br s, 1H, 1-H), 1.53-1.70 (complex m, 7H, 4΄a, 
6΄, 7΄, 8΄, 10΄e-H), 1.74 (s, 1H, 3΄-H), 1.80 (s,1H, 5΄-H), 1.92-2.05 (m, 2H, 1΄, 9΄a-H), 2.86 (d, 
1H, J=12.9 Hz, 10΄a-H), 2.97-3.02 (q, 1H, AMX, A region, JAM=13.8 Hz, JAX=7.6 Hz, 
CHAHMPh), 3.28 (dd, 1H, AMX, M region, JAM=13.8 Hz, JMX=4.0 Hz, CHAHMPh), 3.68-3.71 (q, 
1H, AMX, X region, JAX=7.6 Hz, JMX=4.0 Hz, 6-Hx), 7.16-7.28 (m, 5H, aromatic Η), 7.89 (s, 
1H, 4-H); 13C NMR (100 MHz, CDCl3) δ26.9 (5΄-C), 27.0 (7΄-C), 30.3 (1΄-C), 31.2 (4΄-C), 32.5 
(9΄-C), 33.2 (8΄-C), 33.8 (10΄-C), 34.6 (3΄-C), 36.7 (CH2Ph), 37.9 (6΄-C), 53.6 (6-C), 61.1 (2,2΄-
C), 127.1, 128.7, 129.3 (2, 3, 4, 5, 6-aromatic C), 136.6 (1- aromatic C), 174.1, 174.8 (3, 5-C); 
CΙ+ MS: m/z 325.2 ([M+H]+, 88), 324.2 ([M]+, 21), 233.1 ([M-CH2Ph]+, 66). The hydrochloride 
salt (37.HCl) was prepared as described for 7c.HCl. Mp 185-187 oC (dec). [α]25589 -38 (c 0.2, 
MeOH). Anal. (C20H25Cl N2O2) C, H, N.  
1–Methylspiro[piperazine–2,2΄–tricyclo[3.3.1.13,7]decane]–3,5–dione (6b) 
A solution of diketopiperazine 6a9 (500 mg, 2.13 mmol) in THF-MeOH 1:1 (14 mL), aqueous 
formaldehyde 37 % (1 mL, 12.5 mmol) was stirred for 3 h at room temperature,  and NaCNBH3 
(217 mg, 3.45 mmol) was then added in one portion. After stirring for 20 min the pH of the 
reaction mixture was adjusted to 6-7 by dropwise addition of acetic acid. Stirring was continued 
for 4 h at ambient temperature with the occasional addition of acetic acid to maintain the pH at 
6-7. Solvents were evaporated in vacuo and the residue was treated with water (20 mL), and then 
NaOH 1N and solid Na2CO3 until the pH was adjusted to 8. The off-white solid formed was 
isolated by vacuum filtration, washed with water (2 x 5 mL), and dried. Subsequent purification 
by column chromatography on silica gel using Et2O-n-hexane 4:1 afforded the title compound 6b 
as a white crystalline solid (490 mg, 92%): mp 191-192 0C (CH2Cl2-n-pentane); 1H NMR (400 
MHz , CDCl3) δ1.47 (d, 1H, J=12.0 Hz, 4΄e-H), 1.54 (d, 1H, J=12.3 Hz,  9΄e-H), 1.61-1.91 
(complex m, 7H, 3΄, 5΄, 6΄, 7΄, 8΄e, 10΄e-H), 2.03-2.25 (complex m, 4H, 1΄-H , 4a, 8a, 9a-H), 
2.32 (s, 3H, CH3), 2.76 (d, 1H, J=12.9 Hz, 10΄a-H), 3.25-3.89 (q, 2H, AB, JAB=19.0 Hz, 6-H), 
7.87 (br, s, 1H, 4-H); 13C NMR (100 MHz , CDCl3) δ26.3 (5΄-C), 27.1 (7΄-C), 30.2 (1΄-C), 31.8 
(4΄-C), 32.1 (3΄, 9΄-C), 33.2 (8΄-C), 33.7 (10΄-C
 
), 37.4 (CH3), 37.5 (6΄-C), 53.0 (6-C), 65.7 (2, 
2΄-C), 172.0, 174.1 (3, 5-C). Anal. (C14H20N2O2) C, H, N. 
1–Methyl-3,5–dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetic benzyl ester 
(40) 
Sodium hydride (47 mg, 1.94 mmol) was added portionwise to a stirred solution of 
diketopiperazine 6b (400 mg, 1.61 mmol) in dry DMF (12 mL). After stirring at room 
temperature for 1 h under argon, benzyl bromoacetate (387 mg, 1.69 mmol), dissolved in dry 
DMF (4 mL) was added dropwise. Stirring was continued at rt for 48 h under argon, and the 
reaction mixture was then poured onto ice/water mixture (35 mL), and extracted with Et2O (4x25 
mL). The combined organic extracts were washed with brine (25 mL), dried (Na2SO4), and 
evaporated in vacuo. The oily residue was purified by column chromatography on silica gel 
using Et2O-n-hexane 1:1 to afford the title compound 40 as a colourless viscous oil (530 mg, 
83%):  1H NMR (400 MHz , CDCl3) δ1.49 (dd, 1H, J=2.1, 12.2 Hz, 4΄e-H), 1.55 (dd, 1H, J=2.2, 
12.1 Hz, 9΄e-H),    1.58-1.77 (complex m, 5H, 6΄, 8΄, 10΄e-H), 1.85 (br s, 2H, 5΄, 7΄-H ), 2.06-
2.28 (m, 4H, 1΄, 3΄, 4΄a, 9΄a-H), 2.36 (s, 3H, CH3), 2.76 (d, 1H, J=13.0 Hz, 10΄a-H), 3.36-4.03 
(q, 2H, AB, JAB =19.1 Hz,  6-H), 4.40-4.70 (q, 2H, AB, JAB =16.8Hz, CH2CO2CH2Ph), 5.15 (s, 
2H, CO2CH2Ph), 7.28-7.40 (m, 5H, aromatic Η); 13C NMR (100 MHz , CDCl3) δ 26.3 (5΄-C), 
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27.1 (7΄-C), 30.5 (1΄-C), 31.9 (4΄-C) 32.1 (9΄-C), 32.2 (3΄-C), 33.1 (8΄-C), 33.7 (10΄-C), 37.3 
(CH3), 37.6 (6΄-C), 40.4 (CH2CO2CH2Ph), 53.3 (6-C), 65.5 (2,2΄-C), 67.3 (CO2CH2Ph), 128.3, 
128.4, 128.5 (2, 3, 4, 5, 6-aromatic C), 135.1 (1-aromatic C), 168.0 (CO2CH2Ph), 171.2 , 174.0 
(3, 5-C); CI+ MS: m/z 397.2 ([M+H]+, 23), 396.2 ([M]+, 18), 369.2 (100), 305.1 ([M-CH2Ph]+, 
12). 
1–Methyl-3,5–dioxospiro[piperazine-2,2΄-tricyclo[3.3.1.13,7]decane]-4-acetic acid (41) 
Prepared from the above benzyl ester 40 in an almost quantitative yield by catalytic 
hydrogenolysis in exactly the same procedure described earlier for the preparation of carboxylic 
acid 27.9 White solid: mp 210-212 οC (EtOH-Et2O);  1H NMR (400 MHz , DMSO-d6) δ1.42 (d, 
2H, J=11.9 Hz, 4΄e-H),  1.52 (td, 2H, J=13.8, 16.8 Hz, 8΄e, 9΄e-H), 1.59-1.75 (m, 4H, 6΄, 8΄a, 
10΄e-H),  1.78 (s, 2H, 5΄, 7΄-H), 2.03-2.18 (m, 4H, 1΄,  3΄, 4΄a, 9΄a-H ), 2.31 (s, 3H, CH3), 2.69 
(d, 1H, J=12.2 Hz, 10΄a-H),  3.0-3.85 (v br s, 1H, CO2H), 3.47-3.99 (q, 2H, AB, JAB=19.2 Hz, 6-
H), 4.19-4.39 (q, 2H, AB,  JAB=16.9 Hz,  CH2CO2H); 13C NMR (100 MHz , DMSO-d6)  δ 25.9 
(5΄-C), 26.7 (7΄-C), 30.0 (1΄-C), 31.5 (3 ΄-C),  31.7 (4΄-C), 31.8 (9΄-C),  32.7 (8΄-C), 33.4 (10΄-
C), 36.6 (CH3), 37.3 (6΄-C), 40.2 (CH2CO2H), 52.5 (6-C), 64.8 (2,2΄-C),  169.3 (CO2H), 170.7 , 
173.7 (3, 5-C). Anal. (C16H22N2O4) C, H, N. 
1-Methyl-1,4-diazaspiro[5,7]tridecane-3,5-dione (66) 
Prepared by reductive methylation of diketopiperazine 649 (650 mg, 3.09 mmol) in MeOH-
THF 1:3 (20 mL) as described above for the preparation of compound 6b. The resulting solid 
residue was purified by column chromatography on silica gel using AcOEt-Et2O 1:1 to afford the 
title compound as a white crystalline solid 66 (600 mg, 87%): mp 134-136 οC (CH2Cl2–n-
pentane); 1H NMR (400 MHz , CDCl3) δ1.36-1.68 (complex m, 8H, 8, 9, 10, 11, 12-H) 1.70-
1.87 (m, 4H, 7, 9, 11, 13-H), 2.02-2.08 (~q, 2H, J=8.0 , 9.9 Hz,  7, 13-H), 2.37 (s, 3H, CH3), 3.61 
(s, 2H, 2-H), 8.24 (br s, 1H, 4-H); 13C NMR (100 MHz , CDCl3) δ20.7 (9, 11-C), 24.5 (10-C), 
27.9 (8, 12-C), 29.3 (7, 13-C), 39.3 (CH3), 54.3 (2-C), 64.4 (6-C), 171.3, 176.4 (3, 5-C). Anal. 
(C12H20N2O2). 
 
1-Methyl-3,5-dioxo-1,4-diazaspiro[5.7]tridecane-4-acetic acid benzyl ester (68) 
Prepared from the diketopiperazine 66 in exactly the same procedure described above for the 
preparation of compound 40. The resulting oily residue was purified by column chromatography 
on silica gel eluting first with Et2O-n-hexane 1:1 and then AcOEt-n-hexane 1:1 to afford the title 
compound 68 as a colourless viscous oil (92%): 1H NMR (400 MHz, CDCl3) δ1.38-1.67 
(complex m, 8H, 8, 9, 10, 11, 12-H), 1.70-1.87 (m, 4H, 7, 9, 11, 13-H), 2.0-2.07 (~q, 2H, J=9.3 , 
9.6 Hz, 7, 13-H), 2.39 (s, 3H, CH3), 3.72 (s, 2H, 2-H), 4.54 (s, 2H, CH2CO2CH2Ph), 5.12 (s, 2H, 
CO2CH2Ph), 7.28-7.43 (m, 5H, aromatic Η); 13C NMR (100 MHz ,CDCl3) δ 20.7 (9, 11-C), 24.5 
(10-C), 27.9 (8 , 12-C), 29.8 (7, 13-C), 39.2 (CH3) 39.8 (CH2CO2CH2Ph), 54.5 (2-C), 64.5 (6-C), 
67.3 (CO2CH2Ph), 128.4, 128.5, 128.6 (2, 3, 4, 5, 6-aromatic C), 135.0 (1-aromatic C), 167.8 
(CO2CH2Ph), 170.3, 175.9 (3, 5-C); CΙ+ MS:  m/z   372.3 ([M]+, 34), 373,3 ([M+H]+, 100), 281.1 
([M-CH2Ph]+, 41). 
1-Methyl-3,5-dioxo-1,4-diazaspiro[5.7]tridecane-4-acetic acid (70) 
Prepared from the above benzyl ester 68 in an almost quantitative yield by catalytic 
hydrogenolysis in exactly the same procedure described earlier for the preparation of carboxylic 
acid 27.9 White solid: mp 178-180 ο C (EtOH-Et2O);  1H NMR (400 MHz , DMSO-d6) δ1.20 – 
1.57 (complex m, 8H, 8, 9, 10, 11, 12-H), 1.61-1.83 (complex m, 4H, 7, 9, 11, 13-H), 1.87-2.01 
(m, 2H, 7, 13-H), 2.33 (s, 3H, CH3), 3.72 (s, 2H, 2-H), 3.30-4.90 (v br s, 1H, CO2H), 4.27 (s, 2H, 
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CH2CO2H); 13C NMR (100 MHz , DMSO-d6)  δ 20.7 (9, 11-C), 24.6 (10-C), 27.8 (8 , 12-C), 
29.5 (7 , 13-C), 38.8 (CH3), 39.8 (CH2CO2H), 53.9 (2-C), 64.1 (6-C), 169.5 (CO2H), 170.4 , 
175.8 (3, 5-C). Anal. (C14H22N2O4) C, H, N. 
 
 
Table 2. Antitrypanosome action of acetamide 43, acetohydrazide 44, O-methyl hydroxamate 
45, carboxylic acids 27-31, 41, 56, 59, and 71, 2,6-DKP scaffold molecules 6a, 6b, 37-39, and 64-
67, and acetohydroxamic acid tested against cultured blood stream form T. brucei (pH=7.4). 
Compound(a) IC50 (µM) IC90 (µM) Compound IC50 (µM) IC90 (µM) 
43 200  71 >300  
44 118  6a nab  
45 542  6b na  
27 469  37 63.2 79.2 
28 203 255 38 38.6 57.2 
29 111 203 39 18.5 27.1 
30 171 259 64 na  
31 103 208 65 >400  
41 na  66 na  
56 760  67 >400  
59 >400  Acetohydroxamic 
acid 
680  
aCompounds 45, 29-31, 37, and 38 were tested as hydrochloride salts. 
bData not available. 
 
 
 
 
 
Experimental. Biological Assays. 
 
Trypanocidal assays 
Cultured bloodstream form T. brucei (strain 427) were maintained at 37 oC in modified Iscove’s 
medium (pH 7.4). Trypanocidal activity was assessed by growing parasites for 48 h in the presence 
of various drug concentrations to determine the levels which inhibited growth by 50% (IC50) and 
90% (IC90). In the case of untreated cultures (volume 4 ml), cell densities increased from 0.5×104 
to 1×106 cells ml−1 over this period. Experiments were performed in triplicate. Cell densities at 
each drug concentration were determined using a hemocytometer (Weber Scientific International 
Ltd), and drug sensitivity was expressed as a percentage of growth of control cells. For T. cruzi 
epimastigotes (CL Brener clone), inhibition experiments were carried out in Nunclon 24 well 
plates in 2 ml of growth medium at an initial innoculum of  2 x 105 epimastigotes ml-1. After 5 
days incubation at 28oC in RPMI medium (Kendall et al. 1990) in the absence of drug, cell density 
reached 2 x 107 parasites ml-1.   
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 (25) Kendall, G.; Wilderspin, A. F.; Ashall, F.; Miles, M. A. and Kelly, J. M. Trypanosoma cruzi 
glycosomal glyceraldehyde-3-phosphate dehydrogenase does not conform to the "hotspot" 
topogenic signal model. EMBO J. 1990, 9, 2751-2758 
 
Cytotoxicity tests 
Cytotoxicity against mammalian cells was assessed using microtitre plates as described in Bot et 
al. (2010). Briefly, L6 cells (a rat skeletal muscle line) were seeded at 1 x 104 ml-1 in 200 µl of 
growth medium containing different compound concentrations. The plates were incubated for 6 
days at 37oC and 20 µl Alamar Blue (Biosource UK Ltd.) was then added to each well. After 
further 8 h incubation, the fluorescence was determined using a Gemini fluorescent plate reader 
(Molecular Devices).    
(26) Bot, C.; Hall, B. S.; Bashir, N.; Taylor, M. C.; Helsby, N. A.; Wilkinson, S. R. Trypanocidal 
activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. Agents Chemother. 2010, 54, 4246-
4252. 
 
 
Abbreviation used: RPMI, Roswell Park Memorial Institute. 
 
 
 
 
 
 
 
 
 
Table 3. Elemental analysis data for the tested compounds synthesized in this study. 
 
Compounds 
Molecular 
Formula 
Calculated % Found % 
C H N C H N 
7a C15H21N3O4 58.62 6.89 13.67 58.62 6.98 13.71 
7a.HCl C15H22ClN3O4 52.40 6.45 12.22 52.64 6.61 11.95 
7b C16H23N3O4 59.79 7.21 13.08 59.52 7.30 13.37 
7b.HCl C16H24ClN3O4 53.70 6.76 11.74 53.37 7.06 12.02 
7c.HCl C16H24ClN3O4 53.70 6.76 11.74 53.58 7.16 11.61 
7d.HCl C22H28ClN3O4 60.89 6.50 9.68 61.28 6.71 9.86 
7e.HCl C22H28ClN3O4 60.89 6.50 9.68 60.52 6.77 10.02 
8.HCl C22H28ClN3O4 60.89 6.50 9.68 61.26 6.83 9.91 
9a.HCl C13H22ClN3O4 48.83 6.93 13.14 48.88 7.01 13.07 
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9b.HCl C14H24ClN3O4 50.37 7.25 12.59 50.75 7.60 12.28 
9c.HCl C14H24ClN3O4 50.37 7.25 12.59 50.37 7.60 12.21 
9d.HCl C20H28ClN3O4 58.60 6.89 10.25 58.63 6.99 10.20 
10a.HCl C12H20ClN3O4 47.14 6.59 13.74 46.95 6.72 13.61 
10b.HCl C13H22ClN3O4 48.83 6.93 13.14 48.40 7.28 12.72 
43 C15H21N3O3 61.83 7.27 14.42 61.46 6.89 14.78 
44 C15H22N4O3 58.80 7.24 18.29 58.55 7.13 17.91 
45.HCl C16H24ClN3O4.0.4 Et2O 54.63 7.29 10.86 54.59 7.19 11.09 
29.HCl C22H27ClN2O4 63.07 6.50 6.69 63.08 6.57 6.43 
30.HCl C22H27ClN2O4 63.07 6.50 6.69 62.69 6.73 6.39 
31.HCl C22H27ClN2O4 63.07 6.50 6.69 63.41 6.81 6.31 
41 C16H22N2O4 62.73 7.24 9.15 62.61 7.14 9.23 
59 C12H18N2O4 56.68 7.14 11.02 57.07 7.16 11.38 
71 C13H20N2O4 58.19 7.51 10.44 58.44 7.90 10.18 
6b C14H20N2O2 67.71 8.12 11.28 67.71 8.14 11.25 
37.HCl C20H25ClN2O2 66.56 6.98 7.76 66.95 7.04 7.36 
38.HCl C20H25ClN2O2 66.56 6.98 7.76 66.19 7.22 8.20 
39 C20H24N2O2 74.04 7.46 8.64 74.11 7.44 8.57 
65 C10H16N2O2 61.20 8.22 14.28 61.19 8.52 14.05 
66 C12H20N2O2 64.25 8.99 12.49 64.10 8.99 12.65 
67 C11H18N2O2 62.83 8.63 13.32 63.01 9.02 12.97 
 
